Galloping India Growth For Sacubitril/Valsartan Under Shadow Of Challenge
Executive Summary
Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug it out in court over alleged patent infringement charges.
You may also be interested in...
Pendulum Swings Again: Entresto Patent In India Restored, For Now
Patent pertaining to Novartis’s Entresto re-instated for now in India after a two-judge bench stays a previous order that set aside the grant of the patent. Will that put Indian firms that launched generic versions of the heart failure therapy at risk of infringement in the interim?
Entresto Patent Order Quashed In India, Market Ripe For Action
Court sets aside order pertaining to patent for Novartis’s Entresto in India, setting the stage for high-octane generic competition that potentially includes frontline domestic companies. If the Swiss firm appeals, market dynamics may be impacted but prices of same-composition second brands of the heart-failure therapy are already headed southwards.
Entresto Patent Order Quashed In India, Market Ripe For Action
Court sets aside order pertaining to patent for Novartis’s Entresto in India, setting the stage for high-octane generic competition that potentially includes frontline domestic companies. If the Swiss firm appeals, market dynamics may be impacted but prices of same-composition second brands of the heart-failure therapy are already headed southwards.